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Aims: The cost-effectiveness of screening for silent coronary heart disease (CHD) in type 2 diabetes (DM2) is
still debated.
Methods: We applied a diagnostic algorithm for silent CHD detection, in a cohort of 102 asymptomatic DM2
subjects (57 ± 7 years), attending 5 Italian outpatient clinics, to verify its predictive value. The risk of silent
CHD was calculated considering classical risk factors, and presence of microangiopathy/macroangiopathy.
Patients were divided in 3 groups, i.e. group 1: normal ECG and low silent CHD risk; group 2: abnormal ECG,
irrespective of silent CHD risk; group 3: high silent CHD risk, irrespective of ECG. To group 2 and 3, a functional
test was recommended and performed in 78% of patients.
Results: Silent CHD prevalence was similar in group 2 and 3 (25 vs. 17% respectively; p = 0.495). However,
evaluating the entire cohort, a significant higher prevalence of silent CHD was observed in subjects with
abnormal vs. normal ECG (23 vs. 4%; P = 0.004), but not in subjects with high vs. low pre-test silent CHD risk
(14 vs. 9%; p = 0.472).
Conclusions: AnabnormalECGwasa strong, independentpredictorof silent CHD(OR8.9;CI 1.27–62.5; p = 0.028)
in DM2. Therefore, a functional stress testing should be considered in DM2 patients with ECG abnormalities.© 2017 Elsevier Inc. All rights reserved.1. Introduction
Patientswith type2diabetesmainlydie fromischemicheartdiseaseor
ischemic stroke, so their life expectancy is reduced by at least 6 years
compared to the non-diabetic counterpart.1 Any phenotype of heart
disease significantly associate with diabetes, as recently confirmed in a
wide population study, by Shah et al.2 It is also well documented that
coronary heart disease (CHD) in diabetes is more severe,3 and more
frequent than in non-diabetic subjects: about 75% of diabetic patients
without a diagnosis of CHD show high-grade atherosclerotic coronary
lesions, at post-mortem examination.4 The prevalence of asymptomatic
CHD in this population is round 20%, in most studies,5–9 a figure higher
than the non-diabetic individuals; therefore in type 2 diabetes the
presence of silent myocardial ischemia is highly probable. Asymptomaticclare no potential conflicts of
publication of this article.
– DIMED, Via Giustiniani, 2,
49 8754179.
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urnal of Diabetes and Its Commyocardial ischemia predicts cardiovascular events in this population,
beyond the routine risk prediction.10 For this reason, the
cost-effectiveness of a screening strategy to detect silent CHD has been
proposed although there is no unanimous consensus. Several guidelines
have addressed this issue,11–15 yet recommendations are often
conflicting,16 and a definite proof that screening programs to prevent
cardiac events in patients with type 2 diabetes are worthwhile
cost-effective is lacking. For this reason the Italian Societies for the
Study of Diabetes (Società Italiana di Diabetologia, SID and Associazione
Medici Diabetologi, AMD), and several Italian Societies of Cardiology and
Atherosclerosis (Associazione Nazionale Medici Cardiologi Ospedalieri,
ANMCO, Associazioni Ragionali Cardiologi Ambulatoriali, ARCA, Società
Italianadi Cardiologia, SIC, Società Italianaper lo Studiodell'Aterosclerosi,
SISA) have jointly addressed this topic, by proposing a flow-chart with
the definition of the high risk of silent CHD, along with an instrumental
diagnostic approach to detect silent CHD, in asymptomatic diabetic
patients.17
The main aim of this study was to identify major predictors of silent
coronary artery disease in T2DM patients with a very high pre-test risk
of silent CHD;other aimswere: 1. to verify the adhesion to this proposedry heart disease in patients with type 2 diabetes: application of a
plications (2017), http://dx.doi.org/10.1016/j.jdiacomp.2017.03.014
2 S. Vigili de Kreutzenberg et al. / Journal of Diabetes and Its Complications xxx (2017) xxx–xxxscreening protocol to detect silentmyocardial ischemia infive outpatient
clinics; and 2. to evaluate, in subjects screened for silent CHD, the
cardiovascular outcomes at 12 and 30 months of follow-up.
2. Subjects
Five Italian Diabetes Centers participated in this study, and a total of
102 patients were enrolled. Participating centers were: the out-patient
Diabetes Clinics of Cagliari University, Napoli Federico II University,
Padova University, Pisa University, and S. Giovanni Rotondo (Foggia)
Hospital. Recruitment and baseline clinical evaluations were performed
from January2012 toDecember2012. Consecutivepatients attending the
above-mentioned outpatient clinics, who met the inclusion/exclusion
criteria, were enrolled. Inclusion criteria were: age 35–65 years; type 2
diabetes diagnosed by ADA criteria since at least 1 year; absence of
typical cardiac symptoms (chest discomfort, dyspnea, angina, etc.), and
negative clinical history for cardiac disease; a recent (within 1 month)
electrocardiogram (ECG); definition of the risk of silent myocardial
ischemia on the basis of the Consensus suggested criteria (Fig. 1);
willingness to participate in the study, and to attend periodical follow-up
visits in the respective centers; signed informed consent. Exclusion
criteria were type 1 diabetes; other major organ diseases or advanced
chronic diabetes complications (i.e. chronic kidney disease stage ≥3;
severe proliferative retinopathy; peripheral arterial disease Lériche-
Fontaine stage ≥3), unwilling to participate. The study was approved by
the local Institution and Ethical Committee of the University Hospital of
Padova, and the approval was extended to all other centers.
3. Materials and methods
At baseline visit, clinical history, ongoing therapy, chronic diabetic
complications, and blood pressure measurements were recorded
in each subject. Main anthropometric (weight, height, BMI, waist
circumference), and blood pressure measurements in sitting position
were obtained after an overnight fasting, and a blood sample was
collected to measure clinical chemistry parameters (glucose, glycated
hemoglobin, total cholesterol, HDL cholesterol, triglycerides, AST, ALT,Fig. 1. Definition of the risk of silent myocardial ischemia
Please cite this article as: Vigili de Kreutzenberg S, et al. Silent corona
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(Friedewald formula) and CKD-EPI GFR were also calculated. A urine
spot sample was obtained to measure urinary albumin excretion (as
albumin/creatinine ratio).
The enrolled subjects were then subdivided in the 3 following groups
(Fig. 2): group 1, patients with a normal ECG report, but without a high
probability of silent CHD. An ECG was considered “normal” even with an
incomplete right bundle branch block, or with isolated 1st degree
atrioventricular block; all other ECG interpretations were considered as
“abnormal”; group 2, patients with an abnormal ECG, without a high
probability of silent CHD; group 3, patients with high silent CHD risk,
independent fromECG abnormalities. Patients included in groups 2 and 3
were then suggested to undergo a functional cardiac diagnostic test, in
accordance with the Consensus algorithm (Fig. 2), taking into account
patient's preference/contraindications. An ECG was repeated to patients
allocated in group 1, as suggested, before the follow-up visit. Ongoing
pharmacological therapywaspossiblymodified, during functional cardiac
tests, in accordance with the good clinical practice recommendations.
A first follow-up visit was programmed after 12 months. During this
visit, the diabetologist had: 1. to verify whether the suggested diagnostic
algorithmwas fulfilled; 2. to register the diagnostic test results; and 3. to
collect the main cardiovascular clinical outcomes (acute myocardial
infarction, AMI, transient ischemic attack, TIA, stroke, hospitalization for
heart failure, peripheral by-pass or amputation). The anthropometric and
biochemical parameters were repeated as outlined in baseline (Fig. 2).
A second follow-up visit was programmed after 36 months, for
anthropometric and biochemical parameters, and cardiovascular events
collection. Vital status andmain cardiovascular event (MACE)occurrence
were also investigated afterwards.
All the visits and diagnostic tests were performed in an outpatient
regimen.3.1. Statistical analysis
Continuous variables are expressed as mean ± SD, if normally
distributed ormedian (interquartile range), if non-normally distributed,
and categorical variables as percentage. Comparison between two or, as suggested by the Italian Intersociety Consensus.
ry heart disease in patients with type 2 diabetes: application of a
plications (2017), http://dx.doi.org/10.1016/j.jdiacomp.2017.03.014
Fig. 2. Study protocol.
3S. Vigili de Kreutzenberg et al. / Journal of Diabetes and Its Complications xxx (2017) xxx–xxxmore groups was performed with the Student's t test or ANOVA,
respectively, for continuous variables with normal distribution, and
with Wilcoxon or Kruskal–Wallis test, respectively, for variables with
non-normal distribution, and with the chi-square test for categorical
data. The least significance difference (LSD) post-hoc test was applied. A
multiple logistic regression analysiswas applied to identify the variables
independently associated with CHD.




Main demographic, anamnestic and clinical characteristics of the
whole study cohort and comparisons among the 3 predefined groups, at
baseline visit, are summarized in Table 1. A different sex distribution
was present, among groups; glycated hemoglobin values increased
progressively and significantly from group 1 to 3, while HDL cholesterol
concentrations progressively lowered; similarly, the prevalence of
arterial hypertension, erectile dysfunction, symptomatic peripheral
artery disease, and diabetic retinopathy significantly differed among
groups, being maximal in the high silent CHD probability subjects.
The most frequent recorded ECG abnormalities were specific
alterations of repolarization (n 7), and left axial deviation (n 7). In 4
patients a Qwavewas diagnosed, in 4 patients a bundle branch blocks,
and in 3 patients negative T waves were found.
4.2. Follow-up at 12 months
At first follow-up visit (12 ± 0.9 months) data were collected on
protocol adherence, performed diagnostic test, prevalence of silent CHD
diagnosis, and main clinical and biohumoral parameters. Eighty-six
patients, out of 102 attended the 12-month follow-up visit. The protocolPlease cite this article as: Vigili de Kreutzenberg S, et al. Silent corona
screening approach in a follow-up study. Journal of Diabetes and Its Comadherence, the frequency anddistribution of performeddiagnostic tests,
and the screening test results are summarized in Table 2. None of these
variable showed statistical differences among groups.
In subjects with positive cardiac functional tests, a coronary
angiography (CAG) was performed, to ascertain the presence of
significant (N50%) coronary stenosis. In all but 1 case, showing on the
other hand a positive echo-stress test, silent CHD was confirmed at CAG.
Among subjects showing ECGraphic alterations (group 2), 4 male and 1
female had an ascertained diagnosis of silent CHD, while among subjects
withahighpre-test riskof silentCHD(group3), 4malehadanascertained
diagnosis of silent CHD. Of note, in group 2 only 1 patient showed a high
pre-test silent CHD risk, and had a negative functional test. No patient of
group 1 (normal ECG) showed clinical or ECG/echocardiographic
abnormalities at 12-month follow-up visit.
Interestingly, when we compared subjects with normal (n 70) vs.
abnormal (n 32) ECG, the prevalence of CHDwas significantly higher in
patients with ECG alterations (4% vs. 23%, respectively; p = 0.004),
whereas, when we compared subjects with a low pre-test silent CHD
risk (n71) and subjectswith ahighpre-test risk (n31), a non-significant
differencewas observed for theprevalence of CHDwithin groups (9% vs.
14%, respectively; p = 0.472).
At this follow-up visit, several anthropometric and biohumoral
parameters showed significant improvement, with respect to baseline
(Table 3).
Moreover, 2 cardiovascular events were reported: 1 patient of
group 1 reported a transitory ischemic attack, and 1 patient of group 2
an episode of heart failure.4.3. Diagnosis of silent CHD in patients undergone a functional cardiac test
Whenwe restricted the analysis to subjects undergoing a functional
cardiac screening test (i.e. group 2 and 3; n 44), among patients with
normal (n 16) vs. abnormal (n 28) ECG, the diagnosis of silent CHDwas
confirmed in 2 patients (12.5%) of the former group, but in 7 patientsry heart disease in patients with type 2 diabetes: application of a
plications (2017), http://dx.doi.org/10.1016/j.jdiacomp.2017.03.014
Table 1
Studied variables in the whole cohort, and in predefined subgroups, and comparisons among the 3 subgroups.
Variable All (n 102) Group 1 (n 49) Group 2 (n 23) Group 3 (n 30) p
Age (years) 57 ± 7 56 ± 7 58 ± 7 58 ± 6 0.402
Gender (M/F) 55/47 22/27 9/14 24/6⁎⁎,# 0.002
BMI (kg/m2) 33 ± 8 34 ± 10 32 ± 6 33 ± 7 0.848
Waist (cm) 111 ± 17 113 ± 21 108 ± 16 109 ± 12 0.637
UKPDS CHD risk 17 ± 10 12 ± 6 15 ± 7 27 ± 10⁎⁎,# b0.001
UKPDS fatal CHD risk 10 ± 7 7 ± 5 9 ± 5 17 ± 7⁎⁎,# b0.001
UKPDS stroke risk 7 ± 7 6 ± 4 6 ± 4 10 ± 10⁎⁎,# 0.005
UKPDS fatal stroke risk 1 ± 1 0.8 ± 0.5 0.9 ± 0.6 1.8 ± 1.6⁎⁎,# b0.001
DM duration (years) 7 ± 6 6 ± 6 7 ± 6 8 ± 6 0.717
SBP (mmHg) 138 ± 16 134 ± 12 137 ± 15 147 ± 18⁎⁎,# 0.001
DBP (mmHg) 82 ± 9 82 ± 8 80 ± 11 84 ± 10 0.183
Heart rate (bpm) 78 ± 9 77 ± 8 77 ± 12 80 ± 8 0.268
Glucose (mg/dl) 148 ± 46 137 ± 37 150 ± 59 165 ± 16⁎⁎⁎ 0.032
Glycated haem. (%) 7.7 ± 1.7 7.2 ± 1.5 7.5 ± 1.9 8.6 ± 1.4⁎⁎,§ 0.001
Glycated haem. (Mm) 60 ± 13 55 ± 11 58 ± 15 70 ± 11⁎⁎,§ 0.001
AST (IU/L) 24 ± 11 23 ± 9 23 ± 10 27 ± 15 0.322
ALT (IU/L) 29 ± 20 27 ± 22 29 ± 16 30 ± 21 0.858
Creatinine (mg/dl) 0.92 ± 0.30 0.89 ± 0.27 0.88 ± 0.27 1.00 ± 0.35 0.180
eGFR (ml/min.1.73mq)⁎ 82 ± 20 83 ± 19 82 ± 20 81 ± 23 0.854
AER (median, interquartile range) (mcg/min) 10.00 (4.08–64.60) 7.50 (3.50–15.15) 27.75 (7.70–92.00) 12.00 (2.55–103.95) 0.130
Tot. cholesterol (mg/dl) 197 ± 37 194 ± 34 203 ± 38 197 ± 40 0.365
HDL cholesterol (mg/dl) 48 ± 14 51 ± 14 49 ± 14 41 ± 12⁎⁎,§ 0.003
LDL cholesterol (mg/dl) 119 ± 33 117 ± 31 116 ± 34 119 ± 33 0.453
Triglycerides (mg/dl) 153 ± 103 135 ± 72 158 ± 110 179 ± 133 0.188
Hypertension (%) 80 67 87§ 97⁎⁎ 0.004
Dyslipidemia (%) 68 59 82 73 0.127
Hypotensive drugs (%) 75 58 86⁎⁎ 93⁎⁎ 0.001
Hypolipidemic drugs (%) 58 44 74⁎⁎⁎ 70⁎⁎⁎ 0.016
Antiaggregants (%) 29 18 39 40 0.063
Diet (%) 10 11 5 10 0.782
OAD (%) 77 85 77 63 0.080
Metformin (%) 76 83 77 63 0.146
Sulpho. or glinide (%) 21 24 16 20 0.761
Incretins (%) 16 18 16 13 0.879
Glitazone (%) 5 4 16 0 0.053
Insulin (%) 31 19 40 43⁎⁎⁎ 0.050
OAD + Insulin (%) 17 17 16 17 0.993
Retinopathy (%) 17 6 26⁎⁎⁎ 27⁎⁎⁎ 0.022
Nephropathy (%) 16 8 22 23 0.134
Neuropathy (%) 13 8 22 13 0.278
Claudicatio (%) 8 2 4⁎⁎⁎ 21⁎⁎ 0.009
Erectile dysfunction (%) 7 0 6 19⁎⁎ 0.008
DM = diabetes mellitus; SBP = systolic blood pressure; DBP = diastolic blood pressure; AER = albumin excretion rate; OAD = oral antidiabetic drugs; Sulpho. = sulphonilureas.
(Group 1: normal ECG, and no high risk of silent CHD; group 2: abnormal ECG, independent of the risk of silent CHD; group 3: high silent CHD risk, independent of ECG or
echocardiogram reports.)
Mean ± SD. ANOVA or Kruskal–Wallis test or chi-squared test p-values and post-hoc least significant differences are shown.
⁎ eGFR was calculated with the CKD-EPI method.
⁎⁎ p b 0.005 vs. group 1.
⁎⁎⁎ p b 0.05 vs. group 1.
# p b 0.005 vs. group 2.
§ p b 0.05 vs. group 2.
4 S. Vigili de Kreutzenberg et al. / Journal of Diabetes and Its Complications xxx (2017) xxx–xxx(25%) of the latter; this comparison however does not reach statistical
significance (p = 0.322), probably due to the small numbers. Among
the 7 patients with abnormal ECG and CHD, 3 showed a low pre-test
probability of silent CHD, and 4 a high pre-test probability. On the otherTable 2
Adherence to study protocol, performed diagnostic test, and results of silent CHD screening.
All Grou
Subjects (n) 102 49
Protocol adherence/enrolled patients (y/n) 80/22 (78%) 36/13
12-mo FU visit (yes/no) 86/16 (84%) 36/13





Positive test in screened patients (y/n) 10 (14%) 0 (0%
Ascertained silent CHD by CAG 9 (13%) 0 (0%
FU = follow-up. P for ANOVA or ⁎chi-square test between group 2 and 3; MSCT = multi-s
Please cite this article as: Vigili de Kreutzenberg S, et al. Silent corona
screening approach in a follow-up study. Journal of Diabetes and Its Comhand, both patients with normal ECG and silent CHD showed a high
pre-test risk.
When we compared subjects with high silent CHD risk (n 25),
calculated as suggested by the Consensus score (Fig. 2), vs. subjectswithp 1 Group 2 Group 3 p
23 30
(73%) 20/3 (87%) 24/6 (80%) 0.418
(73%) 22/1 (96%) 28/2 (93%) 0.147





) 5/15 (25%) 5/19 (21%) 0.743⁎
) 5/15 (25%) 4/20 (17%) 0.495⁎
lice computer tomography.
ry heart disease in patients with type 2 diabetes: application of a
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Table 3
Comparison of clinical/biohumoral parameters between baseline and 12-month
follow-up visits (N 86 subjects).
Variable Baseline 12 month
follow-up
p
Weight (kg) 97 ± 26 92 ± 23 0.015
BMI (kg/m2) 34 ± 10 33 ± 8 0.025
Waist (cm) 112 ± 18 113 ± 21 0.014
Glucose (mg/dl) 144 ± 44 134 ± 45 0.017
Glycated haem. (%) 7.8 ± 1.8 7.1 ± 1.4 0.002
Glycated haem. (Mm) 62 ± 14 54 ± 11 0.002
AST (IU/L) 24 ± 11 23 ± 12 0.201
ALT (IU/L) 30 ± 21 28 ± 16 0.427
Creatinine (mg/dl) 0.92 ± 0.29 0.89 ± 0.24 0.035
eGFR (ml/min.1.73mq) 82 ± 20 86 ± 19 0.012
AER (Median, interquartile range)
(mcg/min)
10.00 (4.08–64.60) 14.00 (2.00–108.00) 0.057
Total cholesterol (mg/dl) 203 ± 36 181 ± 33 b0.001
HDL cholesterol (mg/dl) 47 ± 15 47 ± 15 0.925
LDL cholesterol (mg/dl) 128 ± 32 106 ± 25 b0.001
Triglycerides (mg/dl) 157 ± 93 151 ± 87 0.639
5S. Vigili de Kreutzenberg et al. / Journal of Diabetes and Its Complications xxx (2017) xxx–xxxa low pre-test probability (n 19), the prevalence of ascertained silent
CHD was not significantly different between groups, though tended to
be higher in the low risk group (26% vs. 16%; p = 0.462). Similarly,
comparing the patients on the basis of the 10 year UKPDS coronary risk
only, i.e. b20% (n 21) or N20% (n 23), the prevalence of silent CHD was
alike between groups (19% vs. 22%, respectively; p = 0.825).
These results unravel a stronger association between silent CHD
and ECG abnormalities, than between silent CHD and a high disease
probability, based on cardiovascular risk factors.
4.4. Follow-up at 36 months
Themeandurationof this second follow-upvisitwas33 ± 8 months.
Sixty-five percent of the whole group attended the follow-up visit 2
(Table 2). Comparing all studied parameters, between the two follow-up
visits (12- and 36-months), a statistically significant difference was
observed only for LDL-cholesterol, further reduced at the second
follow-up visit (104 ± 25 vs. 97 ± 28 mg/dl; p = 0.050). No other
significant changes were observed. At this follow-up visit, 3 more
cardiovascular events were reported: 2 acute myocardial infarctions and
1TIA inpatients of group3; it is of note that all these3patients showedan
abnormal ECG at baseline.
After a mean period of 33 ± 8 months, all patients were alive.
4.5. Event-free survival at final evaluation
A further follow-up visit for vital status and main cardiovascular
event occurrence was performed at 56 ± 8 months. Vital status was
known for all the subjects; all were alive, but 1 patient of group 3, who
died for pulmonary embolism, after a diagnosis of colon cancer. Data on
MACE were available for 91 subjects (89%), while it was not possible to
collect data on MACE for 11 subjects of the initial cohort, at this finalTable 4
Logistic regression analysis to estimate the risk of CHD (dependent variable) associated
with major CVD-risk variables.
Variables OR 95% CI p
Age (years) 1.031 0.894–1.191 0.672
Gender (M/F) 9.541 0.476–191.139 0.140
BMI (kg/m2) 1.147 0.985–1.336 0.077
UKPDS CHD risk 1.019 0.907–1.145 0.754
ECG abnormalities 8.932 1.275–62.595 0.028
HbA1c (%) 1.094 0.543–2.206 0.801
Dyslipidemia 0.703 0.091–5.465 0.737
Hypertension 0.000 0.000 0.998
For each odds ratio we estimated a two-tailed p values and 95% confidence intervals (CI).
Please cite this article as: Vigili de Kreutzenberg S, et al. Silent corona
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of group2 and oneof group3, experienced anacute coronary syndrome.
4.6. Logistic regression analysis of variables associated with CHD
Looking for variables independently associatedwith the diagnosis of
CHD, we analyzed by logistic regression the role of ECG abnormalities,
UKPDSCHD risk score, hypertension, HbA1c, and dyslipidemia, together
with age, gender and BMI. As shown in Table 4, only ECG abnormalities
were independently associated with CHD (OR 8.932, 95% CI 1.275–
62.595, p b 0.028), further confirming its reliability for the screening of
silent myocardial ischemia.
5. Discussion
The usefulness of screening for asymptomatic CHD in diabetic patients
has long been debated,6,11–16 but still remains uncertain. In this study we
tested the efficacy of the diagnostic algorithm for silent CHD proposed by
the Italian Societies for the Study of Diabetes and Cardiology.17
We found that in a cohort of unselected asymptomatic type 2 diabetic
subjects, the prevalence of silent CHD is 11%; yet this prevalence almost
doubled (20.5%) in patients showing either an abnormal resting ECG or a
high pre-test risk of silent CHD. This figure is comparable to that of other
studies.5,7,8 On theother hand, a low risk of silent CHD, determined by CV
risk factors, or a normal ECGareunlikely to be associatedwith silent CHD.
The high probability of silent CHD, as suggested by our Consensus, is
based either on theUKPDSRiskEngine, and/or on thepresenceofmicro-
and microangiopathy complications, which has been shown to be
significantly associatedwithmacrovascular disease.18,19 Subjectswith a
high risk score were advised to perform a functional cardiac test, which
is also recommended in subjects with an ECG abnormality (apart from
the isolated 1st degree atrioventricular block or the incomplete right
bundle branch block). We observed a similar prevalence of silent CHD
between thosewith high risk, independent of ECGalterations (group 3),
and abnormal ECG, independent of silent CHD risk (group 2). However,
when we considered normal vs. abnormal ECG instead of low vs. high
pre-test silent CHD risk, the presence of ECG abnormalities seemed to
show a better diagnostic performance. To confirm the lesser role of
traditional risk factors in identifying diabetic patients at risk of silent
CHD, when we compared subjects with vs. without a high UKPDS
coronary risk score, the prevalence of ascertained silent CHD between
groups was similar.
Conclusively, logistic regression analyses confirmed the independent
association of ECG abnormalities with silent CHD.
These findings demonstrate, for the first time in a prospective study,
that any ECG alterations should be considered the strongest predictor
for silent CHD, while the traditional risk-based approach to identify
patients to be screened for silent CHD seems to be of lessened
usefulness, as already suggested.20,21 Moreover in this study, not only
ECG alterations suggestive of myocardial infarction were considered for
the diagnosis of silent CHD, as in the population of the UKPDS,5 but
whatever ECG abnormality, strengthening the importance of this test in
evaluating anydiabetic individual. The concept that themanifestation of
cardiovascular disease, rather than the disease risk definition should be
considered in the single patient, has recently been taken into account
and exposed in the 2016 ADA Recommendations. While in the 2015
ADA Position Statement,22 the screening for CHD was tout-court not
recommended, since it failed to improve outcomes, as long as CVD risk
factors were treated, in the 2016 recommendations it is suggested
“to consider investigations for coronary artery disease in the presence of…
signs or symptoms of associated vascular. disease including carotid bruits,
transient ischemic attack, stroke, claudication, or peripheral arterial
disease”.23 This is the first time that overt atherosclerotic disease is
suggested as a criterion for silent CHD risk definition, by ADA
statements. Also in the Italian intersociety Consensus, the presence of
atherosclerosis contributes to the risk definition of silent CHD, butry heart disease in patients with type 2 diabetes: application of a
plications (2017), http://dx.doi.org/10.1016/j.jdiacomp.2017.03.014
6 S. Vigili de Kreutzenberg et al. / Journal of Diabetes and Its Complications xxx (2017) xxx–xxxcompared to this parameter, the presence of specific cardiac alterations,
documented at the ECG recording, shows a more important predictive
value. Therefore, one relevant observation that we can draw from our
results is the importance of performing a standard rest ECG, in all type 2
diabetic patients, every year, as recommended by the Italian Standards
of Care for Diabetes.24
We found an adherence to the suggested diagnostic protocol in
78% of patients, which is not satisfactory, given that the patients were
managed in specialized centers, and informed about their CHD risk.
However, another important result of our study is thatmainmetabolic
parameters improved significantly at 1-year follow-up visit, in the
whole group, although no particular intervention on lifestyle or drug
therapy modifications was given. This observation may suggest that
the perception of a closer and wider medical supervision positively
affects patient behavior, and confirms that better quality of care is
guaranteed in dedicated disease centers.25–27
Finally, we observed too few cardiovascular events to draw any
conclusion about it, being their incidence of about 2% per year, in a
follow-up of 56 months. This result is comparable to that observed in
the subgroup of the DIAD study cohort defined at high-risk by the
UKPDS risk engine (about 2%) .28 However, all but one were observed
in patients with ECG abnormalities, and only 1 event happened in a
low risk subjects with normal ECG.
This study has some limitations, mainly residing in the relatively
small number of participants and in the incomplete fulfillment of the
diagnostic protocol that may reduce the strength of our results; on the
other hand the statistical significance obtained in this small cohort
reveals the robustness of the findings.
In conclusion, the presence of whatever ECG abnormality, and not
only of Q waves or typical ischemic alterations, can be considered a
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